Dipti Talaulikar

Dipti Talaulikar

Canberra, ACT, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 102 publications

Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Erratum: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 27, 2026

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 11, 2026

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Journal: Blood advances

Published: February 05, 2026

Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses.

Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses.

Journal: Blood advances

Published: February 05, 2026

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

Australasian chronic lymphocytic leukaemia consensus statement: 2026 update.

Journal: Internal medicine journal

Published: January 06, 2026

Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma Australia.

Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma Australia.

Journal: Expert review of hematology

Published: October 13, 2025

Re-treatment of relapse in elderly AML with time-limited venetoclax-based regimen: a case report and literature review.

Re-treatment of relapse in elderly AML with time-limited venetoclax-based regimen: a case report and literature review.

Journal: Annals of hematology

Published: October 10, 2025

GB2064 (lenumlostat) shows preliminary evidence of bone marrow collagen fibrosis reduction with manageable tolerability in JAK inhibitor-refractory myelofibrosis: results from the MYLOX-1 phase IIa study.

GB2064 (lenumlostat) shows preliminary evidence of bone marrow collagen fibrosis reduction with manageable tolerability in JAK inhibitor-refractory myelofibrosis: results from the MYLOX-1 phase IIa study.

Journal: Haematologica

Published: September 08, 2025

Recent advances in the understanding of TP53 in haematological malignancies.

Recent advances in the understanding of TP53 in haematological malignancies.

Journal: Pathology

Published: September 01, 2025

Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Journal: Internal medicine journal

Published: August 27, 2025

Adult Acute Myeloid Leukaemia With DDX3X::MLLT10: A Rare Entity With Significant Unmet Clinical Needs.

Adult Acute Myeloid Leukaemia With DDX3X::MLLT10: A Rare Entity With Significant Unmet Clinical Needs.

Journal: EJHaem

Published: August 01, 2025

Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease.

Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease.

Journal: Internal medicine journal

Published: July 04, 2025

Showing 1-12 of 102

Last Updated: 09/26/2026